Controlled release tablet having a unitary core
AssigneeAndrx Pharmaceuticals, Inc.
InventorsChih-Ming Chen, Xiu Xiu Cheng, Joseph Chou, Steve Jan
Life of this patent
Estimating the term…
Abstract
A controlled release pharmaceutical tablet containing antihyperglycemic drug and a hypoglycemic drug that does not contain an expanding or gelling polymer layer and comprising a core containing the antihyperglycemic drug and the hypoglycemic drug, a semipermeable coating membrane surrounding the core and at least one passageway in the membrane to allow the drugs to be released from the core.
Claims39
A controlled release pharmaceutical tablet consisting essentially of:
- (a) a core consisting essentially of:
- (i) buformin or a pharmaceutically acceptable salt thereof;
- (ii) glipizide;
- (iii) polyvinyl pyrrolidone;
- and
- (iv) sodium lauryl sulfate;
- (b) optionally, a seal coat around the core;
- (c) a semipermeable membrane coating covering said core comprising;
- (i) cellulose acetate;
- (ii) polyethylene glycol with an average molecular weight between 380 and 420;
- and
- (iii) a plasticizer;
- and
- (d) at least one passageway in the semipermeable membrane to allow release of the buformin or a pharmaceutically acceptable salt thereof and glipizide from the core to the environment of use to provide therapeutic levels of buformin or a pharmaceutically acceptable salt thereof and glipizide for from 12 to 24 hours.
A controlled release pharmaceutical tablet consisting essentially of:
- (a) a core consisting essentially of:
- (i) metformin or a pharmaceutically acceptable salt thereof;
- (ii) glyburide;
- (iii) polyvinyl pyrrolidone;
- and
- (iv) sodium lauryl sulfate;
- (b) optionally, a seal coat around the core;
- (c) a semipermeable membrane coating covering said core comprising;
- (i) cellulose acetate;
- (ii) polyethylene glycol with an average molecular weight between 380 and 420;
- and
- (iii) a plasticizer;
- and
- (d) at least one passageway in the semipermeable membrane to allow release of the metformin or a pharmaceutically acceptable salt thereof and glyburide from the core to the environment of use to provide therapeutic levels of metformin or a pharmaceutically acceptable salt thereof and glyburide for from 12 to 24 hours.
A controlled release pharmaceutical tablet consisting essentially of:
- (a) a core consisting essentially of:
- (i) buformin or a pharmaceutically acceptable salt thereof;
- (ii) glyburide;
- (iii) polyvinyl pyrrolidone;
- and
- (iv) sodium lauryl sulfate;
- (b) optionally, a seal coat around the core;
- (c) a semipermeable membrane coating covering said core comprising;
- (i) cellulose acetate;
- (ii) polyethylene glycol with an average molecular weight between 380 and 420;
- and
- (iii) a plasticizer;
- and
- (d) at least one passageway in the semipermeable membrane to allow release of the buformin or a pharmaceutically acceptable salt thereof and glyburide from the core to the environment of use to provide therapeutic levels of buformin or a pharmaceutically acceptable salt thereof and glyburide for from 12 to 24 hours.
Dependencies are inferred from the claim text.